6200 Lookout Road
Boulder, CO 80301
United States
720 647 8519
https://www.enliventherapeutics.com
Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 50
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Mr. Samuel S. Kintz M.B.A. | Co-Founder, CEO, Secretary & Director | 866,41k | N/A | 1986 |
Dr. Helen Louise Collins M.D. | Chief Medical Officer | 686,19k | N/A | 1963 |
Mr. Anish Patel Pharm.D. | Co-Founder & COO | N/A | N/A | 1981 |
Mr. Benjamin Hohl | CFO & Head of Corporate Development | 488,5k | N/A | 1990 |
Dr. Galya D. Blachman Esq., Ph.D. | Chief Legal Officer & Head of Business Development | N/A | N/A | 1977 |
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.
Enliven Therapeutics, Inc.s ISS Governance QualityScore, Stand 1. Juni 2024, lautet 6. Die grundlegenden Scores sind Audit: 6, Vorstand: 4, Shareholderrechte: 8, Kompensation: 8.